Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma

Table 2 Univariate analysis of overall survival (OS) for potential prognostic factors of patients with non-metastatic locally recurrent NPC

Variable	Entire cohort (69 patients)		χ²	P value^a	CCRT group (34 patients)		RT group (35 patients)		χ²	P value^a
Variable	n	5-year OS rate (%)	χ²	P value^a	n	5-year OS rate (%)	n	5-year OS rate (%)	χ²	P value^a
Sex			0.810	0.368
Male	57	33.4			27	37.0	30	28.9	1.941	0.164
Female	12	41.7			7	57.1	5	20.0	2.849	0.091
Age (years)			9.656	0.002
≤46	38	46.3			22	43.0	16	50.0	0.039	0.843
>46	31	19.9			12	38.5	19	10.5	3.385	0.066
rT category^b			10.342	0.001
rT1–2	15	72.2			5	100	10	60.0	2.725	0.099
rT3–4	54	24.2			29	33.0	25	13.2	6.789	0.009
rN category^b			0.049	0.824
rN0	59	33.2			30	40.1	29	25.2	3.614	0.057
rN1–2	10	44.4			4	50.0	6	40.0	0.161	0.688
Clinical stage^b			8.613	0.003
I–II	16	67.7			6	83.3	10	60.0	1.042	0.307
III–IV	53	24.7			28	34.3	25	13.2	7.574	0.006
Recurrence interval (months)			0.343	0.558
≤30	39	36.0			21	37.5	18	33.3	0.126	0.723
>30	30	33.4			13	49.0	17	20.6	5.664	0.017
Tumor volume (cm³)			9.352	0.002
≤26	33	51.7			17	42.9	16	56.3	0.023	0.881
>26	36	18.3			17	37.6	19	0.0	7.482	0.006

Abbreviations as in Table 1
^aBy log-rank test
^bRestage according to the 2002 6th edition TNM staging system of the American Joint Commission on Cancer (AJCC)

ISSN: 2523-3548